Yuanhe Pharmaceutical

Yuanhe Biopharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on the development of recombinant adeno-associated virus (rAAV) gene therapies. The company utilizes its proprietary AAV vector platform to design treatments for rare genetic diseases and prevalent chronic conditions, including hematological and ophthalmic disorders. Its lead candidate, YH-001, is an investigational gene therapy for Hemophilia B that has progressed into Phase 1/2 clinical trials. Yuanhe Bio also maintains an integrated capability spanning from early-stage discovery to GMP-compliant manufacturing. The company is supported by a consortium of leading venture capital firms, including Oriza Holdings and Northern Light Venture Capital. By optimizing vector safety and expression efficiency, Yuanhe Bio aims to deliver transformative, one-time curative medicines to patients globally.